Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK contributes to Haiti relief efforts
In keeping with GSK's response to previous natural disasters, we have initiated a program of support for Haiti.
-
GSK exercises option to progress development of ChemoCentryx’s Traficet-EN for the treatment of inflammatory bowel diseases
GlaxoSmithKline(GSK) andChemoCentryx Inc. today announced that GSK has exercised its option to obtain an exclusive license.
-
Revolade (eltrombopag) receives positive opinion in Europe for chronic immune thrombocytopenic purpura
GSK announced today that CHMP has issued a positive opinion for Revolade.
-
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
Next advance in the treatment of cold sores - Strengthens a key OTC franchise
-
GSK publishes speaking, consulting fees paid to US healthcare professionals
Company progresses commitments to increase transparency
-
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated.
-
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
GlaxoSmithKline Biologicals SA (GSK) and Intercell today announced an agreement to form a strategic alliance to accelerate the development.
-
Pre-Budget Report response - GSK comments on patent box
GSK welcomes the introduction of a new measure announced in the Pre-Budget Report to stimulate future investment in the UK.
-
GSK initiates second pivotal Phase III trial for investigational cardiovascular medication Darapladib
GSK today announced initiation of the second large-scale Phase III clinical trial to evaluate long-term treatment.
-
GSK Update: GSK’s Arepanrix™ H1N1 pandemic vaccine prequalified by the World Health Organization
First prequalification for an H1N1 pandemic vaccine
-
GSK completes extension of strategic collaboration with Aspen
GSK announced that yesterday it completed the extension of its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen)
-
GlaxoSmithKline announced as Tier 3 Sponsor as London 2012 anti-doping plans confirmed
GSK becomes Laboratory Services Provider
-
Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan
GlaxoSmithKline (GSK) announced today that it has filed its vaccine for the prevention of rotavirus gastroenteritis.
-
GlaxoSmithKline and Gilead announce agreement to commercialise Viread® for chronic hepatitis B in key Asian countries
GlaxoSmithKline (GSK) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement to commercialise.
-
GSK Regulatory Update: Avodart
GSK expects to resubmit the file shortly. This action is not the result of new findings related to safety or efficacy.
-
Pandemic 2009 Influenza Update: Pandemrix™ data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline (GSK) today announced that over 40 million doses of its adjuvanted pandemic H1N1 vaccine have been distributed to countries.
-
GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction
GSK and Nabi announced an exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine.
-
Pandemic 2009 Influenza Update: US FDA approves GSK’s pandemic H1N1 vaccine
GSK today announced that FDA has approved a sBLA for its unadjuvanted influenza A (H1N1) pandemic vaccine.
-
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries
GSK today announced that it has signed an agreement with WHO to donate 50 million doses of its influenza vaccine.
-
Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®)
The trial involves 168 adults aged over 60 years of age, and was designed to evaluate the tolerability and immunogenicity.
